Novavax (NVAX) Other Accumulated Expenses (2013 - 2026)

Novavax's Other Accumulated Expenses history runs 14 years deep, the most recent figure standing at $132.4 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses fell 6.75% year-over-year to $132.4 million; the TTM figure through Mar 2026 stood at $132.4 million (down 6.75% YoY), while the FY2025 annual figure was $137.8 million, down 37.26% from the prior year.
• Other Accumulated Expenses was $132.4 million for Q1 2026 at Novavax, down from $137.8 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $930.1 million in Q4 2022 to a low of $31.3 million in Q1 2022.
• Historically, Other Accumulated Expenses has averaged $362.1 million across 5 years, with a median of $219.6 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Other Accumulated Expenses jumped 4312.95% in 2022, then plunged 74.51% in 2024.
• A 5-year view of Other Accumulated Expenses shows it stood at $930.1 million in 2022, then dropped by 7.38% to $861.4 million in 2023, then tumbled by 74.51% to $219.6 million in 2024, then slumped by 37.26% to $137.8 million in 2025, then declined by 3.87% to $132.4 million in 2026.
• The last three Other Accumulated Expenses figures came in at $132.4 million (Q1 2026), $137.8 million (Q4 2025), and $138.3 million (Q3 2025), per Business Quant data.